Posted by Michael Wonder on 22 Apr 2024
Alvotech signs US agreement to expand access for newly approved high concentration interchangeable biosimilar to Humira (adalimumab)
19 April 2024 - Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the US market the newly FDA approved high concentration interchangeable biosimilar to Humira.
Alvotech announced today a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the US market, the newly US FDA approved high concentration interchangeable biosimilar to Humira.
